Education
About Us
Working with TipRanks
Follow Us
Hansa Biopharma AB (SE:HNSA)
:HNSA
Earnings Data
Report Date
Apr 23, 2026Before Open (Confirmed)
Period Ending
2026 (Q1)Consensus EPS Forecast
-1.48Last Year’s EPS
-0.55Same Quarter Last Year
Moderate Buy
Based on 2 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Positive
The call presented multiple strong positives: substantial quarter and full-year revenue growth, a successful SEK 671.5M equity raise providing runway into 2027, a BLA submission to the FDA and active U.S. launch preparations, reduced R&D spend and improvement in operating loss, plus upcoming data readouts and European access wins. Offsetting these are material negatives including a failed Phase III in anti‑GBM (no further trials planned), notable commercial headwinds and near-term variability in Europe (notably Germany), ongoing operating losses and cash burn, and reimbursement/pricing uncertainties in the U.S. Overall, management conveyed confidence and a clear plan to execute in 2026, but execution and regulatory outcomes remain key dependencies.Company Guidance
Strong Q4 and Full-Year Revenue Growth
Q4 total revenue SEK 76.0M (up 135% YoY) with Idefirix product sales SEK 61.1M in Q4 (up 139% YoY). Full-year total revenues SEK 222.3M (~USD 25M), reported as a 46% increase versus 2024; full-year product sales reported at SEK 204.7M (company-stated ~46% increase vs prior year).
Successful Equity Financing and Strong Cash Position
Completed a direct share issue of SEK 671.5M (~USD 71.3M) in Q4 2025. Cash and cash equivalents totaled SEK 701M at December 31, 2025; company says this financing funds operations into 2027.
BLA Submission and U.S. Launch Readiness
BLA for Imlifidase submitted to FDA in December 2025; awaiting acceptance and PDUFA date. Pre-commercial U.S. activities underway: NTAP application planned, market-access and field teams expanding, SVP of commercial hired, and supply/distribution planning in progress. Company notes 200 U.S. transplant centers (100 drive 80% of volume) and detailed center-level data to target launch.
Improved Cost Discipline and Reduced R&D Spend
Full-year R&D expense SEK 304.7M in 2025 (reported down ~19% vs 2024). Q4 R&D SEK 74.4M (down 26% YoY). Full-year operating loss SEK 521M, improved by SEK 116M (18%) vs 2024; Q4 operating loss ~SEK 125M, improved ~28% YoY—company attributes improvements to strong revenue growth and expense control.
Robust Clinical & Data Milestones
ConfIdeS trial in the U.S. reported positive readout and data generation; 5-year Idefirix data published (Transplant International). PAES European Phase III readout and additional real-world data expected in 2026. Company plans development of HNSA-5487 toward a late-stage GBS trial in 2026.
European Market Access and Commercial Wins
Reimbursement now secured in 24 countries. Catalonia (Spain) temporary funding approved (logistics/invoicing setup ongoing). Slovakia reimbursement gained in Q4. French ANSM granted special reimbursement for lung transplant use (off-label pathway), indicating KOL-driven access opportunities.
Organizational and Operational Strengthening
Senior leadership strengthened, debt facility renegotiated, European commercial organization reorganized (Max Sakajja appointed to lead Europe/international), and two equity raises completed—company frames 2025 as a year of transformation to position for global competition and execution.
SE:HNSA Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
SE:HNSA Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
Feb 11, 2026 | kr36.98 | kr38.74 | +4.76% |
Oct 30, 2025 | kr34.46 | kr30.66 | -11.03% |
Jul 17, 2025 | kr25.94 | kr27.90 | +7.56% |
Apr 24, 2025 | kr22.30 | kr23.68 | +6.19% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Hansa Biopharma AB (SE:HNSA) report earnings?
Hansa Biopharma AB (SE:HNSA) is schdueled to report earning on Apr 23, 2026, Before Open (Confirmed).
What is Hansa Biopharma AB (SE:HNSA) earnings time?
Hansa Biopharma AB (SE:HNSA) earnings time is at Apr 23, 2026, Before Open (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is the P/E ratio of Hansa Biopharma AB stock?
The P/E ratio of Hansa Biopharma AB is N/A.
What is SE:HNSA EPS forecast?
SE:HNSA EPS forecast for the fiscal quarter 2026 (Q1) is -1.48.